Pharmaceutical Dextran (Glucose) Market Size
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 231.20 Million |
| Market Size (2029) | USD 292.80 Million |
| CAGR (2024 - 2029) | 4.80 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | High |
Major Players.webp){kind=logo}
*Disclaimer: Major Players sorted in no particular order |
Pharmaceutical Dextran (Glucose) Market Analysis
The Pharmaceutical Dextran Market size is estimated at USD 231.20 million in 2024, and is expected to reach USD 292.80 million by 2029, growing at a CAGR of 4.80% during the forecast period (2024-2029).
Dextran, a homopolysaccharide comprising glucose molecules linked by glycosidic bonds, boasts a structure that can be tailored by incorporating diverse hydrophobic molecules. Known for its water solubility, biocompatibility, and biodegradability, dextran and its derivatives are pivotal in drug delivery systems. Notably, they excel in preparing NPs for drug delivery, showing promise in enhancing the oral delivery of active drugs.
Companies are adopting strategic measures such as collaborations and regional expansions to bolster their market presence. For instance, in May 2024, DKSH’s Business Unit Performance Materials, a prominent distributor of specialty chemicals, announced its support for TdB Labs. This collaboration aims to bolster TdB Labs’ pharmaceutical business in India, focusing on dextran derivatives and other polysaccharides tailored for pharmaceutical and diagnostic applications.
The expanding applications of dextran will propel its market share in the coming years. For instance, an article by the National Center for Biotechnology Information in July 2023 highlighted the rising interest in dextran and its derivatives for breast cancer therapy. Researchers have successfully boosted the efficacy of anticancer agents by conjugating dextran with antitumor medications.
Dextran's versatility and expanding applications underscore its significant potential in the pharmaceutical industry. Strategic collaborations and ongoing research further enhance its market prospects, particularly in drug delivery and cancer therapy.
Pharmaceutical Dextran (Glucose) Market Trends
Dextran 40 Holds Significant Market Share in the Pharmaceutical Industry
Dextran 40 is experiencing significant growth due to its diverse pharmaceutical industry applications. Dextran 40, a pharmaceutical-grade ingredient, is an excipient in the final formulations of drug products. It is also pivotal in producing injection and infusion solutions.
Dextran 40, a key segment in medical applications, bolsters segmental growth with its unique benefits. Primarily, it acts as a plasma volume expander, restoring blood volume for patients grappling with hypovolemia or shock. By lowering blood viscosity and thwarting red blood cell clumping, dextran 40 enhances microcirculation and boosts tissue perfusion. Moreover, its antithrombotic nature mitigates clotting risks and doubles as a potent drug carrier, amplifying medication distribution and efficacy. Given its broad medical applicability and stellar safety record, dextran 40 is an indispensable asset in clinical setups.
The rising applications of dextran 40 are set to drive market growth in the coming years. Pharmacosmos A/S is a leading manufacturer that ensures its dextran 40 products meet strict pharmacopoeial standards, including the United States Pharmacopoeia (USP), the European Pharmacopoeia (EP), and the Japanese Pharmacopoeia (JP). The products are available for lyophilization, oral applications, cryopreservation, organ preservation, and as a blood volume expander. Also, dextran 40 is widely used across various molecular weights. It acts as a colloid and expands plasma volume osmotically, replenishing blood plasma lost during severe hemorrhages. Its systemic effects enhance cardiac output and blood flow, thereby facilitating the circulation of red blood cells to microvasculature in vital organs.
Moreover, the market for dextran 40 is further bolstered by its expanding applications. In January 2024, an article published by Verdict Media Limited emphasized the progression of several stem-cell therapies from preclinical stages to advanced clinical trials. Effective treatments rely on developing resilient formulations, particularly those utilizing mesenchymal stem cells (MSCs) and induced pluripotent stem cells (iPSCs). These formulations play a critical role in maintaining cell viability throughout the treatment's lifecycle, from cryopreservation and storage to handling, shipment, and eventual reconstitution before administration to patients. Many of these formulations prominently include dextran 40, often in conjunction with other vital components.
Dextran 40's growing applications and stringent quality standards drive its market dominance. As the pharmaceutical industry continues to innovate, particularly in stem-cell therapies, the demand for dextran 40 is expected to rise, solidifying its significant market share in the coming years.
North America is Expected to Hold a Dominating Market Share During the Forecast Period
The pharmaceutical dextran (glucose) market is set to witness substantial growth over the coming years, with North America expected to hold a dominant market share. Key manufacturers, growing adoption in diverse industries, and a robust consumer base underpin the region's significant presence in the dextran market.
Companies are bolstering their market positions through strategic acquisitions and collaborations. For instance, in August 2023, Biospectra Inc. and BiaSpestra Canada Ltd acquired a majority stake in Polydex Pharmaceuticals Limited. This strategic move provided Biospectra Inc. with direct access to Polydex’s products, including dextran and derivative products, aiding in the expansion and modernization of the GMP (good manufacturing practice) dextran products portfolio. This acquisition also included additional manufacturing capacity and patents, which are expected to enhance production capabilities and product innovation.
Similarly, the burgeoning development of stem cell-based solutions in North America is anticipated to boost the demand for dextran significantly. In April 2023, in the United States, Gamida Cell Ltd reported the FDA's approval for Omisirge (emidubicel-enlv), allogeneic cell therapy. Notably, this therapy incorporates dextran 40 in its cryopreservation process.
The FDA-approved allogeneic cord blood hematopoietic progenitor cell therapy also employs a similar cryopreservation method involving dextran. These advancements highlight the critical role of dextran in cutting-edge medical therapies and its expanding application scope.
North America is poised to lead the pharmaceutical dextran market owing to strategic business moves and enhanced applications, broadening its utility. North America's significant manufacturing infrastructure, bolstered by a thriving consumer base and continuous advancements in dextran applications, solidifies its standing as a key industry player. With the rising demand for dextran, fueled by its diverse applications and crucial medical functions, North America is set to retain and potentially enhance its market dominance in the future.
Pharmaceutical Dextran (Glucose) Industry Overview
The pharmaceutical dextran (glucose) market is consolidated and consists of a selective number of major players. Both regional and global players in the healthcare industry are increasingly turning to vertical collaboration as a key strategy to bolster their market positions. As emerging nations witness a surge in the adoption of digital health technologies, they are transforming into battlegrounds for intense competition. Some market players in the pharmaceutical dextran (glucose) market are Pharmacosmos A/S, Polydex Pharmaceuticals Limited, Meito Sangyo Co. Ltd, Jinyang Pharm, and pK Chemicals A/S.
Pharmaceutical Dextran (Glucose) Market Leaders
-
PHARMACOSMOS A/S
-
Polydex Pharmaceuticals Limited.
-
Meito Sangyo Co., Ltd.
-
Jinyang Pharm
-
pK Chemicals A/S
*Disclaimer: Major Players sorted in no particular order
Pharmaceutical Dextran (Glucose) Market News
- January 2024: Ildong Pharmaceutical announced a strategic move by signing an eye drop co-promotion agreement with Hanlim Pharm. This collaboration aims to facilitate Ildong's entry into the OTC (over-the-counter) segment of the ophthalmology market. The agreement spotlights Numaren Eye Drops, a hypromellose-dextran formulation designed to address dry eyes and tear production deficiencies.
- August 2023: The Drug Administration of Vietnam and the Ministry of Health licensed the import of 17,010 bags of dextran infusion. These imports were specifically for infirmaries lacking circulation registration, which aligned with prevailing regulations. The Ministry of Health emphasized dextran's significance as a high molecular weight solution, particularly in treating patients with dengue shock syndrome.
Pharmaceutical Dextran (Glucose) Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Adoption of Dextran In Numerous Pharmaceutical Applications
4.2.2 Growing Demand For Blood Plasma Substitutes
4.3 Market Restraints
4.3.1 High Production Costs
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD)
5.1 By Power Type
5.1.1 Dextran 20
5.1.2 Dextran 40
5.1.3 Dextran 60
5.1.4 Dextran 70
5.1.5 Other Power Types
5.2 By Application
5.2.1 Vaccines
5.2.2 Eye Care
5.2.3 Protein Stabilization
5.2.4 Cryopreservation
5.2.5 Oral Application
5.2.6 Other Applications
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Rest of World
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 PHARMACOSMOS A/S
6.1.2 Polydex Pharmaceuticals Limited
6.1.3 Meito Sangyo Co. Ltd
6.1.4 Jinyang Pharm
6.1.5 pK Chemicals A/S
6.1.6 Pfizer Inc.
6.1.7 Merck KGaA
6.1.8 Central Drug House
6.1.9 Otto Chemie Pvt. Ltd
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Pharmaceutical Dextran (Glucose) Industry Segmentation
Dextran, a viscous polysaccharide produced through bacterial action on sucrose, is widely utilized in various applications, including confections, lacquers, and, most notably, medicine, as an extender for blood plasma.
The pharmaceutical dextran (glucose) market is segmented into power type, application, and geography. By power type, the market is segmented into dextran 20, dextran 40, dextran 60, dextran 70, and other power types. By application, the market is segmented into vaccines, eye care, protein stabilization, cryopreservation, oral application, and other applications. By geography, the market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. For each segment, the market sizing and forecasts are based on revenue (USD).
| By Power Type | |
| Dextran 20 | |
| Dextran 40 | |
| Dextran 60 | |
| Dextran 70 | |
| Other Power Types |
| By Application | |
| Vaccines | |
| Eye Care | |
| Protein Stabilization | |
| Cryopreservation | |
| Oral Application | |
| Other Applications |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| Rest of World |
Pharmaceutical Dextran (Glucose) Market Research FAQs
How big is the Pharmaceutical Dextran Market?
The Pharmaceutical Dextran Market size is expected to reach USD 231.20 million in 2024 and grow at a CAGR of 4.80% to reach USD 292.80 million by 2029.
What is the current Pharmaceutical Dextran Market size?
In 2024, the Pharmaceutical Dextran Market size is expected to reach USD 231.20 million.
Who are the key players in Pharmaceutical Dextran Market?
PHARMACOSMOS A/S, Polydex Pharmaceuticals Limited., Meito Sangyo Co., Ltd., Jinyang Pharm and pK Chemicals A/S are the major companies operating in the Pharmaceutical Dextran Market.
Which is the fastest growing region in Pharmaceutical Dextran Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Pharmaceutical Dextran Market?
In 2024, the North America accounts for the largest market share in Pharmaceutical Dextran Market.
What years does this Pharmaceutical Dextran Market cover, and what was the market size in 2023?
In 2023, the Pharmaceutical Dextran Market size was estimated at USD 220.10 million. The report covers the Pharmaceutical Dextran Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Pharmaceutical Dextran Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Pharmaceutical Dextran (Glucose) Industry Report
Statistics for the 2024 Pharmaceutical Dextran (Glucose) market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Pharmaceutical Dextran (Glucose) analysis includes a market forecast outlook for 2024 to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
